Takeda Pharmaceutical Q1 Net Profit Rises 30%, Revenue Down 8.4%

Takeda Pharmaceutical's Q1 net profit rose 30% to ¥124.24bn ($836.8m), beating estimates. Revenue declined 8.4% to ¥1.107trn, while operating profit increased 11% to ¥184.57bn. The Japanese drugmaker maintained its FY22 earnings outlook, expecting revenue of ¥4.53trn, operating profit of ¥475.00bn, and net profit of ¥228.00bn.

Takeda Pharmaceutical Company Limited (NYSE: TAK) reported a significant increase in net profit for the first quarter of fiscal year 2025, climbing 30% to ¥124.24 billion ($836.8 million), according to its latest earnings report [2]. This figure exceeded analysts' estimates, demonstrating robust financial performance. Revenue, however, declined by 8.4% to ¥1.107 trillion, while operating profit surged by 11% to ¥184.57 billion [2].

The Japanese drugmaker's earnings were bolstered by a rise in operating profit, driven by lower impairment and restructuring expenses. Takeda's chief financial officer, Milano Furuta, commented on the impact of VYVANSE generic erosion, stating that it was significant but consistent with expectations, and there was no change to the full-year outlook announced in May [1].

Takeda maintained its fiscal-year 2025 earnings outlook, expecting annual revenue of ¥4.53 trillion, operating profit of ¥475.00 billion, and net profit of ¥228.00 billion. These figures reflect the company's commitment to its strategic goals and its ability to navigate market challenges [1, 3].

The company also achieved several milestones in its research and development pipeline. Notably, Phase 3 studies of oveporexton, an investigational oral orexin receptor 2-selective agonist designed to restore signaling and address the underlying orexin deficiency that causes narcolepsy type 1, met all primary and secondary endpoints [2].

References:
[1] https://seekingalpha.com/news/4474020-takeda-pharmaceutical-non-gaap-eps-of-15100-revenue-of-11067b-reaffirms-fy-outlook
[2] https://www.marketscreener.com/news/takeda-pharmaceutical-s-first-quarter-net-profit-jumped-30-ce7c5fdfd98cf220
[3] https://www.marketscreener.com/news/takeda-pharmaceutical-company-limited-reaffirms-earnings-guidance-for-the-fiscal-year-2025-ce7c5fdfd98df420